Mus vs Sao Tome and Principe: HIV-positive TB patients on ART (antiretroviral therapy)
Mus
100.0%
in 2024
Sao Tome and Principe
100.0%
in 2024
Mus rank
1st
Sao Tome and Principe rank
1st
HIV-positive TB patients on ART (antiretroviral therapy) over time
- Mus
- Sao Tome and Principe
How they compare
Mus currently reports 100.0% against 100.0% in Sao Tome and Principe, a difference of 0.0%.
The two have swapped places 3 times across 18 shared years of data; in 2007 it was Mus ahead.
Mus ranks 1st and Sao Tome and Principe ranks 1st of 2 regions.
Across the 3 decades both report, Mus averaged higher in 1 and Sao Tome and Principe in 1.
Head to head by decade
| Decade | Mus | Sao Tome and Principe | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 69.0% | 34.0% | 35.0% | Mus |
| 2010s | 86.2% | 95.4% | 9.2% | Sao Tome and Principe |
| 2020s | 100.0% | 100.0% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv-positive tb patients on art (antiretroviral therapy), Mus or Sao Tome and Principe?
- Mus, at 100.0% against 100.0% in Sao Tome and Principe as of 2024.
- What is the difference in hiv-positive tb patients on art (antiretroviral therapy) between Mus and Sao Tome and Principe?
- 0.0%, with Mus ahead.
- How many years of comparable data are there for Mus and Sao Tome and Principe?
- 18 years are reported by both, from 2007 to 2024.
- How do Mus and Sao Tome and Principe rank globally for hiv-positive tb patients on art (antiretroviral therapy)?
- Mus ranks 1st and Sao Tome and Principe ranks 1st of 2 regions.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as HIV-positive TB patients on ART (antiretroviral therapy) (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.